Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

Pandemic preparedness: new vaccines are not enough

Maurizia Mezza and Stuart Blume 23rd February 2023

Rapid deployment of vaccines is the key lesson being taken from the Covid-19 pandemic. It should not be the only one.

Now Covid-19 has been displaced from media headlines by war and natural disasters, most people are happy to forget about viruses. Virologists, however, are worried by rapidly-spreading bird flu and the countless other viruses with the potential to infect and spread among mammals—potentially including humans.

Partly due to ecological deterioration and climate change, the risk of such zoonotic disease outbreaks is indeed growing. The need to prepare for a possible future pandemic is widely accepted, although no one can predict its onset. Nor is it clear which kind of virus might be involved. The experience with SARS-CoV-2 over the past two to three years should however be drawn upon.

Record time

Crucial to control of the Covid-19 pandemic was the development, testing and production of vaccines in record time: it was a mere 326 days from release of the virus’ genetic sequence to authorisation of the first vaccines. This lesson, already being drawn, plays into widespread faith in technological solutions to social and environmental problems.

For the Oslo-based Coalition for Epidemic Preparedness Innovations, speed of vaccine development is indeed key. At the end of 2022, CEPI issued a report detailing how future pandemic-beating vaccines could be produced in just 100 days.

Other lessons which can and should be drawn from the Covid-19 experience cannot however count on similar support. In 2020, before a vaccine became available, the constant refrain was ‘when there’s a vaccine life will return to normal’. The socially and politically complex questions which would still have to be tackled, though foreseeable, were ignored.



Don't miss out on cutting-edge thinking.


Join tens of thousands of informed readers and stay ahead with our insightful content. It's free.



These included inequitable access to vaccines, liability in the event of vaccine-related injury, and vaccine refusal and hesitancy. Policy-makers began to address these issues only later, when vaccination campaigns were well under way in much of the world.

Now there is a risk that epidemic preparedness is again being dominated by a single-minded focus on technological solutions. This despite evidence that in Europe public confidence in vaccines and vaccination is actually falling: people are less convinced now than before that vaccines are safe and effective. Unwillingness to accept a Covid-19 vaccine was often due to fear of side-effects. Where is reassurance to come from?

Pharmacovigilance

Post-marketing detection, analysis and prevention of adverse effects of a vaccine or a drug is known as pharmacovigilance. Pharmacovigilance observes the way medicines work in real-life settings and their risk-benefit balance. The pharmacovigilance of vaccines thus monitors adverse events and safety issues that emerge after the vaccine has been approved. This can lead to modification of the group for whom the vaccine is recommended and potentially its withdrawal from the market.

Eudravigilance was established in 2001 as a system for managing and analysing information on suspected adverse drug reactions (ADRs) across the European Economic Area. Pharmacovigilance systems played an important role during the Covid-19 pandemic.

Until recently, national pharmacovigilance centres collected reports on ADRs only from healthcare professionals and pharmaceutical companies. In 2003, Denmark and the Netherlands became the first countries to allow patients and consumers to report suspected ADRs directly. Italy (2004), the United Kingdom (2005) and Sweden (2008) followed suit.

Key insights

Research shows that that ADRs can be identified and described sooner by consumers and patients themselves. Their reports can provide key insights regarding drug-related problems. Since 2012, EU-wide legislation has required that patients be able to report suspected ADRs to competent authorities.

A recent review of Dutch experience of public participation in pharmacovigilance was very positive. A review in the UK showed growing numbers of ADRs identified by patients. Yet enabling patients to report does not mean that they will do so. The literature shows that many are not aware they can report or where they should do so.

The number of reports submitted directly by patients and consumers to Eudravigilance rose more than five-fold (+443 per cent) between 2020 and 2021. Reports related to Covid-19 vaccines accounted for 87 per cent of these. Nevertheless, in much of the world direct patient reporting remains an unfamiliar practice.

Pharmacovigilance agencies have introduced new reporting tools, including mobile applications. While these have led to more reports, this is still not enough. Building mutual trust requires more, and patient engagement should go beyond providing personal data.

Important role

Pharmacovigilance is not acknowledged as the key component of epidemic preparedness it ought to be. Pharmacovigilance centres must engage with civil society—and not only as a source of data. Information has to flow both ways, and in this patient and health-advocacy organisations could play an important role. What information regarding possible adverse events would the public like to see collected? Do people trust that their reports are taken seriously? What kind of feedback or reporting to the community would be best?

Responses to the Covid-19 pandemic have shown the value of a well-functioning pharmacovigilance system.Yet this is still far from being a democratic, transparent and accessible space where civil society can negotiate rights and duties. Most studies of pharmacovigilance in practice focus on ways of enhancing statistical confidence in causal relationships between a vaccine and any associated symptoms.

But public confidence is not the same as statistical confidence. Enhancing pharmacovigilance systems, and supporting civil society’s participation in them, should be an important part of epidemic preparedness. What will be the value of having a vaccine in less than 100 days if many citizens do not trust it?

Maurizia Mezza
Maurizia Mezza

Maurizia Mezza is a doctoral candidate in medical anthropology at the University of Amsterdam, focusing on epidemiological studies and pharmacovigilance in relation to HPV and Covid-19 vaccination.

Stuart Blume
Stuart Blume

Stuart Blume is emeritus professor of science and technology studies at the University of Amsterdam and author of Immunization: How Vaccines Became Controversial (Reaktion Books, 2017).

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

u4219834670 4977 8362 2b68e3507e6c 2 Europe’s Far Right Copies Trump—And It’s WorkingPaul Mason
u421983467645c be21 1cdd415d1c01 2 America’s Systemic Chaos Strategy: Europe Must Forge a New PathMario Pianta
u42198346ae 124dc10ce3a0 0 When Ideology Trumps Economic InterestsDani Rodrik
u4219834676e9f0d82cb8a5 2 The Competitiveness Trap: Why Only Shared Prosperity Delivers Economic Strength—and Resilience Against the Far RightMarija Bartl

Most Popular Articles

u4219834647f 0894ae7ca865 3 Europe’s Businesses Face a Quiet Takeover as US Investors CapitaliseTej Gonza and Timothée Duverger
u4219834674930082ba55 0 Portugal’s Political Earthquake: Centrist Grip Crumbles, Right AscendsEmanuel Ferreira
u421983467e58be8 81f2 4326 80f2 d452cfe9031e 1 “The Universities Are the Enemy”: Why Europe Must Act NowBartosz Rydliński
u42198346761805ea24 2 Trump’s ‘Golden Era’ Fades as European Allies Face Harsh New RealityFerenc Németh and Peter Kreko

Eurofound advertisement

Ageing workforce
The evolution of working conditions in Europe

This episode of Eurofound Talks examines the evolving landscape of European working conditions, situated at the nexus of profound technological transformation.

Mary McCaughey speaks with Barbara Gerstenberger, Eurofound's Head of Unit for Working Life, who leverages insights from the 35-year history of the European Working Conditions Survey (EWCS).

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Foundation for European Progressive Studies Advertisement

Spring Issues

The Summer issue of The Progressive Post is out!


It is time to take action and to forge a path towards a Socialist renewal.


European Socialists struggle to balance their responsibilities with the need to take bold positions and actions in the face of many major crises, while far-right political parties are increasingly gaining ground. Against this background, we offer European progressive forces food for thought on projecting themselves into the future.


Among this issue’s highlights, we discuss the transformative power of European Social Democracy, examine the far right’s efforts to redesign education systems to serve its own political agenda and highlight the growing threat of anti-gender movements to LGBTIQ+ rights – among other pressing topics.

READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

S&D Group in the European Parliament advertisement

Cohesion Policy

S&D Position Paper on Cohesion Policy post-2027: a resilient future for European territorial equity

Cohesion Policy aims to promote harmonious development and reduce economic, social and territorial disparities between the regions of the Union, and the backwardness of the least favoured regions with a particular focus on rural areas, areas affected by industrial transition and regions suffering from severe and permanent natural or demographic handicaps, such as outermost regions, regions with very low population density, islands, cross-border and mountain regions.

READ THE FULL POSITION PAPER HERE

ETUI advertisement

HESA Magazine Cover

With a comprehensive set of relevant indicators, presented in 85 graphs and tables, the 2025 Benchmarking Working Europe report examines how EU policies can reconcile economic, social and environmental goals to ensure long-term competitiveness. Considered a key reference, this publication is an invaluable resource for supporting European social dialogue.

DOWNLOAD HERE

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

BlueskyXWhatsApp